Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00500617 · ClinicalTrials.gov registry record
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
A clinical trial of Cardiovascular Diseases and Coronary Artery Disease, sponsored by CardioDx.
- Completed
- Registry status
- 4,350
- Enrollment target
- 10
- Study locations
NCT00500617: Completed study of Cardiovascular Diseases and Coronary Artery Disease, sponsored by CardioDx.
NCT00500617 is a study of Cardiovascular Diseases and Coronary Artery Disease that has completed, run by CardioDx. The registered enrollment target is 4,350 participants, below the 26,960-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (84% lower). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00500617, a study of Cardiovascular Diseases and Coronary Artery Disease, has completed, sponsored by CardioDx.
- COMPLETED
- Registry status
- 4,350 participants
- Enrollment target
- 10
- Study locations
Study Summary
The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of multiple genes from circulating peripheral blood cells to assess the presence of clinically significant CAD in a patient.
Primary Outcome
The primary analysis will be performed during the third segment of the study using a subset of the enrolled subjects ("primary subjects"). The primary endpoint for the PREDICT study is a validated algorithm that can accurately classify subjects with and without any coronary artery lesion with a ≥50% diameter stenosis, as measured by Core Laboratory blinded quantitative coronary angiography. In evaluating this endpoint, subjects will be classified as either cases or controls. The endpoint will be
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Corus CAD (ASGES)
Study Locations (10)
California
- CV Medical Group Southern California - Beverly Hills
- Scripps HealthCare - La Jolla
Alaska
- Alaska Heart Institute - Anchorage
District of Columbia
- Washington Hospital Medical Center - Washington D.C.
Georgia
- Fuqua Heart Center of Atlanta - Atlanta
Minnesota
- Minneapolis Heart Institute - Minneapolis
North Carolina
- Duke University Medical Center - Durham
Pennsylvania
- Allegheny Hospital - Pittsburgh
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,350 participants |
| Start Date | 2007-07 |
| Est. Completion | 2011-09 |
What the finished NCT00500617 record still lists
NCT00500617 is an observational study that tracks outcomes without assigning an intervention. Its 4,350 participants enrollment target places it among the larger protocols in the corpus, below the 26,960-participant average among 300 other Cardiovascular Diseases trials with a reported enrollment target (84% lower).
The record links to 8 conditions, with Cardiovascular Diseases appearing as the primary indexed condition, and to 1 intervention - of which Corus CAD (ASGES) is the first listed.
NCT00500617 lists 10 locations in 9 states (California, Alaska, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT00500617 about?
NCT00500617 is a clinical study titled "Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree". The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD). The Corus CAD (Age/Sex/Gene Expression score - ASGES) will use quantitative real-time PCR (RT-PCR) to quantify the expression of mul...
What is the current status of trial NCT00500617?
This trial is currently completed. The enrollment target is 4,350 participants. The study started on 2007-07. Estimated completion is 2011-09.
What conditions does trial NCT00500617 study?
This clinical trial studies the following conditions: Cardiovascular Diseases, Coronary Artery Disease, Chest Pain, Coronary Heart Disease, Angina Pectoris.
What interventions are being tested in trial NCT00500617?
The interventions under investigation include: Corus CAD (ASGES) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT00500617?
This trial is sponsored by CardioDx, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00500617 being conducted?
This trial has 10 study locations across Alaska, California, District of Columbia, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00500617's enrollment target sits among peer trials
4,350 27th of 300 higher than 274 of 300 other Cardiovascular Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
The Influence of Chardonnay Marc Intake on Gut and Cardiometabolic Health
RECRUITING · NA
-
TRANSCRIBE (Transcriptomic Analysis of Left Ventricular Gene Expression)
RECRUITING
-
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
RECRUITING · NA
-
Insomnia Treatment and Cardiometabolic Health in Older Adults With Posttraumatic Stress Disorder
RECRUITING · NA
-
Deep Brain Stimulation Motor Ventral Thalamus (VOP/VIM) for Restoration of Speech and Upper-limb Function in People With Subcortical Stroke
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05910567 · 4,346 participants · NA
A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma
- NCT07044297 · 4,390 participants · Phase 3
A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)
- NCT02660645 · 4,400 participants
Blue Light Cystoscopy With Cysview® Registry
- NCT05774951 · 4,300 participants · Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia